Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27088108 | 0.95 | USP30 (0.37) | USP30FFAR1BACE1BACE2RET | |
| SCHEMBL30813409 | 0.89 | USP30 (0.39) | USP30BACE1BACE2AAK1PDPK1 | |
| SCHEMBL30813583 | 0.87 | USP30 (0.38) | USP30BACE1BACE2AAK1 | |
| SCHEMBL27217891 | 0.87 | USP30 (0.38) | USP30BACE1BACE2AAK1 | |
| SCHEMBL27217794 | 0.84 | USP30 (0.37) | USP30BACE1BACE2 | |
| SCHEMBL30813487 | 0.83 | USP30 (0.44) | USP30BACE1BACE2AAK1PDPK1 | |
| SCHEMBL21221307 | 0.81 | USP30 (0.39) | USP30BACE1BACE2 | |
| SCHEMBL29998193 | 0.80 | RET (0.34) | RETPDPK1 | |
| SCHEMBL30813509 | 0.80 | USP30 (0.39) | USP30BACE1BACE2 | |
| SCHEMBL30813573 | 0.80 | USP30 (0.38) | USP30BACE1BACE2AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317758-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-09-26 | — | — | US | disclosed |
| US-20240158394-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-05-16 | — | — | US | disclosed |
| WO-2024059200-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-4320127-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2022216680-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317758-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | USP30 2703/4885FFAR1 1656/4885BACE1 232/4885 |
| US-20240158394-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | USP30 1845/4885FFAR1 2766/4885BACE1 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.